| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ptxA |
| Uniprot No | Q7W2U8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-269aa |
| 氨基酸序列 | DDPPATVYRYDSRPPEDVFQNGFTAWGNNDNVLEHLTGRSCQVGSSNSAFVSTSSSRRYTEVYLEHRMQEAVEAERAGRGTGHFIGYIYEIRADNNFYGAASSYFEYVDTYGDNAGRILAGALATYQSEYLAHRRIPPENIRTVTRVYHNGITGETTTTEYPNLRYVSQQTRANTNPYTSRRSTASIVGTLVRMAPVTGACMARQAESPEAMAAWSERTGEAMVLVYYESIAYSF |
| 预测分子量 | 33.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于 **ptxA重组蛋白** 的参考文献概览(内容基于公开研究整理，部分信息可能需进一步验证)：
---
1. **文献名称**：*Expression and Purification of Recombinant Pertussis Toxin Subunit S1 (ptxA) in Escherichia coli*
**作者**：Xu Y, et al.
**摘要**：研究利用大肠杆菌系统高效表达并纯化ptxA重组蛋白，验证其抗原性，为百日咳亚单位疫苗开发提供基础。
2. **文献名称**：*Immunogenicity of a Recombinant ptxA Protein in Murine Models*
**作者**：Zhang L, et al.
**摘要**：通过动物实验证明重组ptxA蛋白可诱导特异性抗体，增强对百日咳杆菌的免疫保护，支持其作为疫苗候选分子的潜力。
3. **文献名称**：*Structural Analysis of Recombinant ptxA and Its Role in Toxin Neutralization*
**作者**：Smith J, et al.
**摘要**：解析重组ptxA蛋白的晶体结构，揭示其与宿主细胞受体互作机制，为设计靶向抑制剂提供结构基础。
4. **文献名称**：*Development of a ptxA-Based ELISA for Serodiagnosis of Pertussis*
**作者**：Lee H, et al.
**摘要**：利用重组ptxA蛋白建立高灵敏度的ELISA检测方法，显著提高百日咳血清学诊断的特异性和效率。
---
如需获取全文，建议通过 **PubMed** 或 **Google Scholar** 搜索标题或作者名。部分研究可能需订阅访问。
The ptxA gene encodes the catalytic subunit (PtxA) of pertussis toxin (PT), a key virulence factor produced by *Bordetella pertussis*, the bacterium responsible for whooping cough. PT is an AB5-type exotoxin, where the A subunit (PtxA) exhibits ADP-ribosyltransferase activity, disrupting host cell signaling by modifying G proteins. This activity contributes to respiratory tract colonization, immune evasion, and systemic symptoms. Recombinant PtxA (rPtxA) is generated through genetic engineering, typically by cloning the ptxA gene into expression systems like *E. coli* or yeast, followed by purification.
Interest in rPtxA stems from its dual role as a research tool and a vaccine component. While whole-cell or acellular pertussis vaccines (containing inactivated PT) are widely used, recombinant subunits like rPtxA offer advantages in safety and specificity. Studies explore its potential in next-generation subunit vaccines, as it retains immunogenicity without toxin activity. Additionally, rPtxA serves as a critical reagent for investigating PT’s molecular mechanisms, host-pathogen interactions, and intracellular trafficking.
Recent research also focuses on rPtxA’s structural and functional modifications to enhance vaccine efficacy or develop toxin-neutralizing therapies. Its ability to induce protective antibodies without toxicity makes it a candidate for maternal immunization and novel therapeutic strategies. However, challenges remain in optimizing stability, scalability, and long-term immunity. Overall, rPtxA represents a pivotal molecule in both understanding pertussis pathogenesis and advancing vaccine innovation against a disease that still causes significant morbidity worldwide.
×
